Clovis Taps Into Rich "A" Round, Grabs Licensing Rights to Improved Gemcitabine
This article was originally published in The Pink Sheet Daily
Executive Summary
Clovis takes over work on Clavis's pancreatic cancer drug and will develop a companion test to target patients who fare poorly on Lilly's current standard of care.